Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Summary of findings – denosumab vs placebo

BMD Z score (wrist) · adults with β‐thalassaemia and low bone mass

Summary of findings – denosumab showed no clear difference in BMD Z score (wrist) compared with placebo (low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Low

Summary of findings – denosumab vs placebo

Incidence of fractures · adults with β‐thalassaemia and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – denosumab vs placebo

Mobility · adults with β‐thalassaemia and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – denosumab vs placebo

Quality of life · adults with β‐thalassaemia and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – denosumab vs placebo

Adverse effects of treatment · adults with β‐thalassaemia and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

BMD Z score (total hip/femoral neck) · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonates vs placebo or no treatment

BMD Z score (wrist) · adults with β‐thalassaemia and osteoporosis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

BMD Z score (lumbar spine) · women with low bone mass and β‐thalassaemia

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings – strontium ranelate vs placebo

BMD Z score (wrist) · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Incidence of fractures · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Mobility · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Quality of life (back pain VAS score in cm) · women with low bone mass and β‐thalassaemia

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings – strontium ranelate vs placebo

Adverse effects of treatment · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonates vs placebo or no treatment

Incidence of fractures · adults with β‐thalassaemia and osteoporosis

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Moderate

Bisphosphonates vs placebo or no treatment

Mobility · adults with β‐thalassaemia and osteoporosis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonates vs placebo or no treatment

Quality of life (change in mean back pain) · adults with β‐thalassaemia and osteoporosis

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Very low

Bisphosphonates vs placebo or no treatment

Adverse effects of treatment · adults with β‐thalassaemia and osteoporosis

It is very uncertain whether summary of findings – bisphosphonates changes adverse effects of treatment compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
OR 15
2 studies · 143 participants
Very low

Intervention not reported

BMD Z score (total hip/femoral neck) · people with β‐thalassaemia and osteoporosis

It is very uncertain whether the intervention changes BMD Z score (total hip/femoral neck) (very low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Intervention not reported

BMD Z score (lumbar spine) · people with β‐thalassaemia and osteoporosis

It is very uncertain whether the intervention changes BMD Z score (lumbar spine) (very low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
MD 0.43 [0.1, 0.76]
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 147 participants
Low